1. Rethinking osteoporosis drugs : can we simultaneously address sarcopenia?Zoran Gavrilov, Jasna Lojk, 2025, pregledni znanstveni članek Povzetek: Osteoporosis and sarcopenia are two aspects of the geriatric syndrome that frequently occur together and affect one another in a condition referred to as osteosarcopenia. Preventive and treatment options for osteosarcopenia exist but are mainly focused on the treatment of osteoporosis, as there is still no FDA-approved treatment for sarcopenia. Drugs for osteoporosis include antiresorptive and anabolic drugs and hormonal replacement therapies and are prescribed based on age, BMD and other patient characteristics, which, however, do not include the possible co-existence of sarcopenia. As several studies and clinical trials have shown that the pharmacological treatment of osteoporosis can also affect muscle tissue, in either a positive or negative manner, sarcopenia should be another factor affecting the choice of treatment, especially when facing equal treatment options for osteoporosis. The aim of this review was to summarize our current knowledge on the effects of FDA-approved drugs for the treatment of osteoporosis on muscle quality, mass and function. A better understanding of the effects that certain drugs have on muscle tissue might in the future help us to simultaneously at least partially also address the wasting of muscle tissue and avoid further pharmacologically induced decline.
Ključne besede: osteoporosis, sarcopenia, osteosarcopenia, pharmacological treatment
Objavljeno v DiRROS: 09.12.2025; Ogledov: 722; Prenosov: 123
 Celotno besedilo (1,50 MB)
Gradivo ima več datotek! Več... |
2. A cross-sectional study of laboratory parameters 5–6 months after the first COVID-19 infectionTaja Zore, Jasna Lojk, Katarina Reberšek, Elizabeta Božnar Alič, Urška Čegovnik Primožič, Alenka France Štiglic, Aleš Jerin, Irena Prodan Žitnik, Helena Podgornik, Nada Snoj, Barbara Ostanek, Gabriele Turel, Tatjana Lejko-Zupanc, Janja Marc, Darko Černe, 2025, izvirni znanstveni članek Povzetek: Objectives: Despite extensive study of COVID-19 disease, only a few studies also addressed the aftermath of the disease and potential long-term consequences. The aim of this study was to assess COVID-19 resolution through the cross-sectional analysis of an extensive range of haematological and biochemical laboratory parameters and to find potential markers still associated with disease severity 5-6-months post infection.
Methods: In this study, we analysed 92 routine biochemical, haematological and immunological parameters in 75 non-vaccinated patients 5–6 months after recorded first time SARS-CoV-2 infection without reinfection. Demographic and disease severity data were obtained through surveys.
Results: The majority of analysed parameters were within the normal reference intervals, however, statistically significant correlations with the disease severity were detected in 15 parameters: B lymphocytes, NK cells, interleukin (IL)-12, IL-1β, cortisol, ferritin, SARS-CoV-2 specific IgG and IgM antibodies, Na, Cl, creatinine, alkaline phosphatase, cholesterol, HbA1c and alpha 2 and beta 2 globulin fractions of the proteinogram.
Conclusions: Although most observed parameters returned to their normal reference intervals, significant correlations were still observed with disease severity, that could indicate either the pre-infection baseline state which affected disease outcome or minor remaining alterations in function of certain organs, pertaining their stress or damage during the acute phase of the disease.
Ključne besede: disease severity, laboratory parameters, resolution, COVID-19, SARS-CoV-2, laboratory diagnosis
Objavljeno v DiRROS: 07.11.2025; Ogledov: 357; Prenosov: 157
Celotno besedilo (3,36 MB)
Gradivo ima več datotek! Več... |
